The therapeutic potential of GPR43: A novel role in modulating metabolic health

Cellular and Molecular Life Sciences

Volumn 70, Issue 24, 2013, Pages 4759-4770

  Cornall, Lauren M ^a   Mathai, Michael L ^a   Hryciw, Deanne H ^b   McAinch, Andrew J ^a  

^a VICTORIA UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adipogenesis; GPR43; Muscle; Obesity; Short chain fatty acids

Indexed keywords

G PROTEIN COUPLED RECEPTOR 43; REGULATOR PROTEIN; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

ADIPOGENESIS; CARCINOGENESIS; GASTROINTESTINAL TRACT FUNCTION; HUMAN; INTRACELLULAR SIGNALING; LIGAND BINDING; METABOLIC REGULATION; MUSCLE METABOLISM; NONHUMAN; OBESITY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; TISSUE DISTRIBUTION; WEIGHT CONTROL;

ANIMALS; FATTY ACIDS, VOLATILE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; LIGANDS; METABOLIC DISEASES; MODELS, BIOLOGICAL; MUSCLES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

EID: 84889881184     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1419-9     Document Type: Review

References (127)

1. Lundstrom K (2006) Latest development in drug discovery on G protein-coupled receptors. Curr Protein Pept Sci 7(5):465-470
2. Le Poul E et al (2003) Functional characterization of human receptors for short-chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278(28):25481-25489
3. Brown AJ et al (2003) The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short-chain carboxylic acids. J Biol Chem 278(13):11312-11319
4. Cummings JH et al (1987) Short-chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28(10):1221-1227
5. Vinolo MA et al (2011) Regulation of inflammation by short-chain fatty acids. Nutrients 3(10):858-876
6. Zhou J et al (2008) Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab 295(5):E1160-E1166
7. Keenan MJ et al (2006) Effects of resistant starch, a non-digestible fermentable fiber, on reducing body fat. Obesity (Silver Spring) 14(9):1523-1534
8. Bindels LB et al (2012) Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br J Cancer 107(8):1337-1344
9. Tedelind S et al (2007) Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 13(20):2826-2832
10. Marsland BJ (2012) Regulation of inflammatory responses by the commensal microbiota. Thorax 67(1):93-94
11. Hinnebusch BF et al (2002) The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 132(5):1012-1017
12. Bindels LB, Dewulf EM, Delzenne NM (2013) GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci 34(4):226-232
13. Nilsson NE et al (2003) Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun 303(4):1047-1052
14. Xiong Y et al (2004) Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci USA 101(4):1045-1050
15. Swaminath G (2008) Fatty acid binding receptors and their physiological role in type 2 diabetes. Arch Pharm (Weinheim) 341(12):753-761
16. Tazoe H et al (2008) Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J Physiol Pharmacol 59(Suppl 2):251-262
17. Hudson BD et al (2012) Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J Biol Chem 287(49):41195-41209
18. Macfarlane S, Macfarlane GT (2003) Regulation of short-chain fatty acid production. Proc Nutr Soc 62(1):67-72
19. Pomare EW, Branch WJ, Cummings JH (1985) Carbohydrate fermentation in the human colon and its relation to acetate concentrations in venous blood. J Clin Invest 75(5):1448-1454
20. Siler SQ, Neese RA, Hellerstein MK (1999) De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. Am J Clin Nutr 70(5):928-936
21. Kim KA et al (2012) High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One 7(10):e47713
22. de Wit N et al (2012) Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am J Physiol Gastrointest Liver Physiol 303(5):G589-G599
23. Turnbaugh PJ et al (2009) A core gut microbiome in obese and lean twins. Nature 457(7228):480-484
24. Kimura I et al (2013) The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 4:1829
25. Lee T et al (2008) Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol Pharmacol 74(6):1599-1609
26. Wang Y et al (2010) The first synthetic agonists of FFA2: discovery and SAR of phenylacetamides as allosteric modulators. Bioorg Med Chem Lett 20(2):493-498
27. Swaminath G et al (2010) Allosteric rescuing of loss-of-function FFAR2 mutations. FEBS Lett 584(19):4208-4214
28. Smith NJ et al (2011) Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol 80(1):163-173
29. Schmidt J et al (2011) Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem 286(12):10628-10640
30. Hudson BD et al (2013) Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem 288(24):17296-17312
31. Brantis CE, Ooms F, Bernard F (2011) Novel amino acid derivatives and their use as GPR43 receptor modulators. Patent no. WO2011092284
32. Saniere LRM et al (2012) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases. Patent no. WO2012098033A1
33. Cox MA et al (2009) Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E(2) and cytokines. World J Gastroenterol 15(44):5549-5557
34. Cornall LM et al (2011) Diet-induced obesity up-regulates the abundance of GPR43 and GPR120 in a tissue specific manner. Cell Physiol Biochem 28(5):949-958
35. Karaki S et al (2008) Expression of the short-chain fatty acid receptor, GPR43, in the human colon. J Mol Histol 39(2):135-142
36. Hong YH et al (2005) Acetate and propionate short-chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology 146(12):5092-5099
37. Zaibi MS et al (2010) Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short-chain fatty acids. FEBS Lett 584(11):2381-2386
38. Dewulf EM et al (2010) Inulin-type fructans with prebiotic properties counteract GPR43 overexpression and PPARgamma-related adipogenesis in the white adipose tissue of high-fat diet-fed mice. J Nutr Biochem 22(8):712-722
39. Kaji I et al (2011) Density distribution of free fatty acid receptor 2 (FFA2)-expressing and GLP-1-producing enteroendocrine L cells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide. J Mol Histol 42(1):27-38
40. Hatanaka H et al (2010) Identification of transforming activity of free fatty acid receptor 2 by retroviral expression screening. Cancer Sci 101(1):54-59
41. Tang Y et al (2011) G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. Int J Cancer 128(4):847-856
42. Stoddart LA et al (2008) Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short-chain fatty acids. J Biol Chem 283(47):32913-32924
43. Hudson BD et al (2012) Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J 26(12):4951-4965
44. Yonezawa T, Kobayashi Y, Obara Y (2007) Short-chain fatty acids induce acute phosphorylation of the p38 mitogen-activated protein kinase/heat shock protein 27 pathway via GPR43 in the MCF-7 human breast cancer cell line. Cell Signal 19(1):185-193
45. Seljeset S, Siehler S (2012) Receptor-specific regulation of ERK1/2 activation by members of the "free fatty acid receptor" family. J Recept Signal Transduct Res 32(4):196-201
46. Vinolo MA et al (2011) SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. PLoS One 6(6):e21205
47. Liu T et al (2012) Short-chain fatty acids suppress lipopolysaccharide- induced production of nitric oxide and proinflammatory cytokines through inhibition of NF-kappaB pathway in RAW264.7 cells. Inflammation 35(5):1676-1684
48. Sina C et al (2009) G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol 183(11):7514-7522
49. Zarubin T, Han J (2005) Activation and signaling of the p38 MAP kinase pathway. Cell Res 15(1):11-18
50. Maslowski KM et al (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461(7268):1282-1286
51. Karaki S et al (2006) Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell Tissue Res 324(3):353-360
52. - secretion and free fatty acid receptor 2 (FFA2, GPR43) expression in the guinea pig distal colon. Pflugers Arch 461(1):141-152
53. Fukumoto S et al (2003) Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 284(5):R1269-R1276
54. Tolhurst G et al (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61(2):364-371
55. Matricon J (2010) Immunopathogenesis of inflammatory bowel disease. Med Sci (Paris) 26(4):405-410
56. Seidell JC (2000) Obesity, insulin resistance and diabetes - a worldwide epidemic. Br J Nutr 83(Suppl 1):S5-S8
57. Bonow RO et al (2002) World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 106(13):1602-1605
58. Hu FB (2011) Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 34(6):1249-1257
59. Dorn JM et al (1997) Body mass index and mortality in a general population sample of men and women. The Buffalo health study. Am J Epidemiol 146(11):919-931
60. Rosengren A, Wedel H, Wilhelmsen L (1999) Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study. Eur Heart J 20(4):269-277
61. Bjursell M et al (2011) Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab 300(1):E211-E220
62. Ge H et al (2008) Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 149(9):4519-4526
63. Nakano R et al (2006) Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Biochem Pharmacol 72(1):42-52
64. Medina-Gomez G, Gray S, Vidal-Puig A (2007) Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr 10(10A):1132-1137
65. Ahmed K, Tunaru S, Offermanns S (2009) GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors. Trends Pharmacol Sci 30(11):557-562
66. Prieur X et al (2008) Leptin regulates peripheral lipid metabolism primarily through central effects on food intake. Endocrinology 149(11):5432-5439
67. Solinas G et al (2004) The direct effect of leptin on skeletal muscle thermogenesis is mediated by substrate cycling between de novo lipogenesis and lipid oxidation. FEBS Lett 577(3):539-544
68. Roman EA et al (2010) Central leptin action improves skeletal muscle AKT, AMPK, and PGC1 alpha activation by hypothalamic PI3 K-dependent mechanism. Mol Cell Endocrinol 314(1):62-69
69. Akasaka Y et al (2009) Chronic leptin treatment stimulates lipid oxidation in immortalized and primary mouse skeletal muscle cells. Biochim Biophys Acta 1791(2):103-109
70. Donahoo WT et al (2010) Leptin increases skeletal muscle lipoprotein lipase and postprandial lipid metabolism in mice. Metabolism 60(3):438-443
71. McAinch AJ et al (2007) Leptin stimulation of COXIV is impaired in obese skeletal muscle myotubes. Obes Res Clin Pract 1(1):53-60
72. Hamrick MW et al (2010) The adipokine leptin increases skeletal muscle mass and significantly alters skeletal muscle miRNA expression profile in aged mice. Biochem Biophys Res Commun 400(3):379-383
73. Sainz N et al (2009) Leptin administration favors muscle mass accretion by decreasing FoxO3a and increasing PGC-1alpha in ob/ob mice. PLoS One 4(9):e6808
74. Kelesidis T et al (2010) Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 152(2):93-100
75. Myers MG Jr et al (2010) Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab 21(11):643-651
76. Mitterberger MC et al (2010) Adipokine profile and insulin sensitivity in formerly obese women subjected to bariatric surgery or diet-induced long-term caloric restriction. J Gerontol A Biol Sci Med Sci 65(9):915-923
77. Yoon MJ et al (2006) Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 55(9):2562-2570
78. Dyck DJ, Heigenhauser GJ, Bruce CR (2006) The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf) 186(1):5-16
79. Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26(3):439-451
80. Matsubara M, Maruoka S, Katayose S (2002) Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 147(2):173-180
81. Sheng T, Yang K (2008) Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 35(6):321-326
82. Sowers JR (2008) Endocrine functions of adipose tissue: focus on adiponectin. Clin Cornerstone 9(1):32-38 discussion 39-40
83. Baron AD et al (1988) Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol 255(6 Pt 1):E769-E774
84. Zurlo F et al (1990) Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest 86(5):1423-1427
85. Barger PM, Kelly DP (2000) PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 10(6):238-245
86. Young ME, McNulty P, Taegtmeyer H (2002) Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 105(15):1861-1870
87. Coort SL et al (2007) Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: role of sarcolemmal substrate transporters. Mol Cell Biochem 299(1-2):5-18
88. Buchanan J et al (2005) Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146(12):5341-5349
89. Duncan JG (2011) Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta 1813(7):1351-1359
90. Kim JY et al (2000) Lipid oxidation is reduced in obese human skeletal muscle. Am J Physiol Endocrinol Metab 279(5):E1039-E1044
91. Lee JS et al (2006) Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: role of intramuscular accumulation of lipid metabolites. J Appl Physiol 100(5):1467-1474
92. Aguer C et al (2010) Intramyocellular lipid accumulation is associated with permanent relocation ex vivo and in vitro of fatty acid translocase (FAT)/CD36 in obese patients. Diabetologia 53(6):1151-1163
93. Bonen A et al (2004) Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36. FASEB J 18(10):1144-1146
94. Bruce CR et al (2003) Muscle oxidative capacity is a better predictor of insulin sensitivity than lipid status. J Clin Endocrinol Metab 88(11):5444-5451
95. Griffin ME et al (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48(6):1270-1274
96. Pagliassotti MJ et al (1997) Reduced insulin suppression of glucose appearance is related to susceptibility to dietary obesity in rats. Am J Physiol 272(4 Pt 2):R1264-R1270
97. Fujishiro M et al (2001) MKK6/3 and p38 MAPK pathway activation is not necessary for insulin-induced glucose uptake but regulates glucose transporter expression. J Biol Chem 276(23):19800-19806
98. Somwar R et al (2001) GLUT4 translocation precedes the stimulation of glucose uptake by insulin in muscle cells: potential activation of GLUT4 via p38 mitogen-activated protein kinase. Biochem J 359(Pt 3):639-649
99. Sweeney G et al (1999) An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes. J Biol Chem 274(15):10071-10078
100. Babraj JA et al (2009) Blunting of AICAR-induced human skeletal muscle glucose uptake in type 2 diabetes is dependent on age rather than diabetic status. Am J Physiol Endocrinol Metab 296(5):E1042-E1048
101. Turcotte LP, Raney MA, Todd MK (2005) ERK1/2 inhibition prevents contraction-induced increase in plasma membrane FAT/CD36 content and FA uptake in rodent muscle. Acta Physiol Scand 184(2):131-139
102. de Alvaro C et al (2004) Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 279(17):17070-17078
103. Aguirre V et al (2002) Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277(2):1531-1537
104. Green CJ et al (2011) Counter modulation of fatty acid-induced proinflammatory NFβB signalling in rat skeletal muscle cells by AMPK. Biochem J 435(2):463-474
105. Coll T et al (2006) Palmitate-mediated downregulation of peroxisome proliferator-activated receptor-gamma coactivator 1alpha in skeletal muscle cells involves MEK1/2 and nuclear factor-kappaB activation. Diabetes 55(10):2779-2787
106. Bueno OF et al (2000) The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19(23):6341-6350
107. Ueyama T et al (2000) Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. J Mol Cell Cardiol 32(6):947-960
108. Palanivel R et al (2007) Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc Res 75(1):148-157
109. Dong F, Ren J (2009) Adiponectin improves cardiomyocyte contractile function in db/db diabetic obese mice. Obesity (Silver Spring) 17(2):262-268
110. Fujioka D et al (2006) Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am J Physiol Heart Circ Physiol 290(6):H2409-H2416
111. Chai W et al (2012) Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61(4):888-896
112. Zhao T et al (2006) Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317(3):1106-1113
113. Small CJ, Bloom SR (2004) Gut hormones and the control of appetite. Trends Endocrinol Metab 15(6):259-263
114. Flint A et al (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101(3):515-520
115. Mendieta-Zeron H, Lopez M, Dieguez C (2008) Gastrointestinal peptides controlling body weight homeostasis. Gen Comp Endocrinol 155(3):481-495
116. Liu Q et al (2010) Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 9:76
117. Batterham RL, Bloom SR (2003) The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci 994:162-168
118. Ballantyne GH (2006) Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions. Obes Surg 16(5):651-658
119. van den Hoek AM et al (2004) PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 53(8):1949-1952
120. van den Hoek AM et al (2007) Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol Endocrinol Metab 292(1):E238-E245
121. Khan WI, Ghia JE (2010) Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol 161(1):19-27
122. Halford JC, Harrold JA (2012) 5-HT(2C) receptor agonists and the control of appetite. Handb Exp Pharmacol 209:349-356
123. Hajduch E et al (1999) Serotonin (5-Hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle. J Biol Chem 274(19):13563-13568
124. Tulipano G, Spano P, Cocchi D (2008) Effects of olanzapine on glucose transport, proliferation and survival in C2C12 myoblasts. Mol Cell Endocrinol 292(1-2):42-49
125. Halford JC et al (2005) Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets 6(2):201-213
126. Davis RP et al (2013) One-month serotonin infusion results in a prolonged fall in blood pressure in the deoxycorticosterone acetate (DOCA) salt hypertensive rat. ACS Chem Neurosci 4(1):141-148
127. Gergs U et al (2013) Human 5-HT(4) receptor stimulation in atria of transgenic mice. Naunyn Schmiedebergs Arch Pharmacol 386(5):357-367